Advanced Cellular Therapeutics Facility
The Advanced Cellular Therapeutics (ACT) Facility was established in 2015 to support clinical trials requiring human cellular therapy products at UNC Lineberger Comprehensive Cancer Center. Cellular therapy products are generated and expanded in this facility for patients receiving adoptive cell therapy for the treatment of cancer. The ACT Facility includes core staff who are highly experienced in the manufacture of a wide variety of cellular therapy products.
The ACT Facility prepares clinical grade cellular therapy products that are classified as minimal or more-than-minimally manipulated and must be manufactured under current Good Manufacturing/ Tissue Practices (cGMP/cGTP). The facility provides the required infrastructure, including documentation and systems, to prepare, test and release the cellular products in compliance with federal and state regulatory requirements.
In addition to cellular therapy products, the ACT Facility produces retroviral vectors to support ex vivo genetic modification required in some cellular products. The facility includes a dedicated virus production suite with appropriate HVAC systems.
The ACT Facility is located approximately five miles from the University of North Carolina at Chapel Hill campus. The proximity to UNC facilitates collaboration between facility staff and campus faculty. It also greatly reduces the time it takes to develop and deliver cellular therapy products for patients being treated at UNC.
